Literature DB >> 31026814

Outcome analysis of surgery for symptomatic spinal metastases in long-term cancer survivors.

Ori Barzilai1, Lily McLaughlin1, Eric Lis2, Yoshiya Yamada3, Mark H Bilsky1,4, Ilya Laufer1,4.   

Abstract

OBJECTIVEAs patients with metastatic cancer live longer, an increased emphasis is placed on long-term therapeutic outcomes. The current study evaluates outcomes of long-term cancer survivors following surgery for spinal metastases.METHODSThe study population included patients surgically treated at a tertiary cancer center between January 2010 and December 2015 who survived at least 24 months postoperatively. A retrospective chart and imaging review was performed to collect data regarding patient demographics; tumor histology; type and extent of spinal intervention; radiation data, including treatment dose and field; long-term sequelae, including local tumor control; and reoperations, repeat irradiation, or postoperative kyphoplasty at a previously treated level.RESULTSEighty-eight patients were identified, of whom 44 were male, with a mean age of 61 years. The mean clinical follow-up for the cohort was 44.6 months (range 24.2-88.3 months). Open posterolateral decompression and stabilization was performed in 67 patients and percutaneous minimally invasive surgery in 21. In the total cohort, 84% received postoperative adjuvant radiation and 27% were operated on for progression following radiation. Posttreatment local tumor progression was identified in 10 patients (11%) at the index treatment level and 5 additional patients had a marginal failure; all of these patients were treated with repeat irradiation with 5 patients requiring a reoperation. In total, at least 1 additional surgical intervention was performed at the index level in 20 (23%) of the 88 patients: 11 for hardware failure, 5 for progression of disease, 3 for wound complications, and 1 for postoperative hematoma. Most reoperations (85%) were delayed at more than 3 months from the index surgery. Wound infections or dehiscence requiring additional surgical intervention occurred in 3 patients, all of which occurred more than a year postoperatively. Kyphoplasty at a previously operated level was performed in 3 cases due to progressive fractures.CONCLUSIONSDurable tumor control can be achieved in long-term cancer survivors surgically treated for symptomatic spinal metastases with limited complications. Complications observed after long-term follow-up include local tumor recurrence/progression, marginal tumor control failures, early or late hardware complications, late wound complications, and progressive spinal instability or deformity.

Entities:  

Keywords:  EBRT = external beam radiation therapy; KPS = Karnofsky Performance Scale; MIS = minimally invasive surgery; NOMS = neurological, oncological, mechanical instability, and systemic status and comorbidities; SBRT = stereotactic body radiation therapy; metastatic epidural spinal cord compression; oncology; outcomes; radiation; spine; surgery; tumor

Year:  2019        PMID: 31026814     DOI: 10.3171/2019.2.SPINE181306

Source DB:  PubMed          Journal:  J Neurosurg Spine        ISSN: 1547-5646


  4 in total

1.  Endoscopic surgical treatment for symptomatic spinal metastases in long-term cancer survivors.

Authors:  Albert E Telfeian; Adetokunbo Oyelese; Jared Fridley; Cody Doberstein; Ziya L Gokaslan
Journal:  J Spine Surg       Date:  2020-06

Review 2.  Spinal metastasis: narrative reviews of the current evidence and treatment modalities.

Authors:  Pilan Jaipanya; Pongsthorn Chanplakorn
Journal:  J Int Med Res       Date:  2022-04       Impact factor: 1.573

3.  The Role of Minimal Access Surgery in the Treatment of Spinal Metastatic Tumors.

Authors:  Ori Barzilai; Mark H Bilsky; Ilya Laufer
Journal:  Global Spine J       Date:  2020-05-28

Review 4.  Factors associated with spinal fixation mechanical failure after tumor resection: a systematic review and meta-analysis.

Authors:  Zhenyu Cai; Yongzhao Zhao; Xiaodong Tang; Rongli Yang; Taiqiang Yan; Wei Guo
Journal:  J Orthop Surg Res       Date:  2022-02-20       Impact factor: 2.359

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.